Neil Kumar - Aug 16, 2024 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Chief Executive Officer, Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Aug 16, 2024
Transactions value $
-$1,363,067
Form type
4
Date filed
8/20/2024, 06:31 PM
Previous filing
May 17, 2024
Next filing
Nov 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise +55.5K +1.13% 4.95M Aug 16, 2024 Direct F1
transaction BBIO Common Stock Tax liability -$687K -28.1K -0.57% $24.40 4.92M Aug 16, 2024 Direct F2
transaction BBIO Common Stock Sale -$395K -16.2K -0.33% $24.39 4.9M Aug 19, 2024 Direct F3, F4
transaction BBIO Common Stock Sale -$281K -11.2K -0.23% $25.13 4.9M Aug 19, 2024 Direct F3, F5
holding BBIO Common Stock 1.01M Aug 16, 2024 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. F6
holding BBIO Common Stock 996K Aug 16, 2024 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Restricted Stock Units Options Exercise $0 -2.39K -33.33% $0.00 4.79K Aug 16, 2024 Common Stock 2.39K Direct F1, F7
transaction BBIO Restricted Stock Units Options Exercise $0 -33.5K -9.09% $0.00 335K Aug 16, 2024 Common Stock 33.5K Direct F1, F8
transaction BBIO Restricted Stock Units Options Exercise $0 -19.6K -6.67% $0.00 274K Aug 16, 2024 Common Stock 19.6K Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 55,537 shares of Common Stock underlying the Reporting Person's RSUs.
F3 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
F4 Represents the weighted average sale price of the shares sold ranging from $23.91 to $24.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5 Represents the weighted average sale price of the shares sold ranging from $24.91 to $25.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F6 The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F7 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F8 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F9 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.